Welcome to datamethods
|
|
1
|
9889
|
July 24, 2018
|
Appropriate statistical tests for my study?
|
|
1
|
67
|
March 22, 2023
|
Tool for assessing study validity
|
|
1
|
36
|
March 22, 2023
|
Minimal Detectable Change (MDC) vs Minimal Clinically Important Difference (MCID)
|
|
6
|
197
|
March 22, 2023
|
ROC has a S shape, why?
|
|
18
|
395
|
March 21, 2023
|
Choice of study design
|
|
0
|
49
|
March 20, 2023
|
RMS Causal Inference
|
|
39
|
15927
|
March 20, 2023
|
Progression in cancer trials
|
|
14
|
335
|
March 18, 2023
|
Individual response
|
|
233
|
25341
|
March 18, 2023
|
Randomization in a diagnostic study - necessary?
|
|
3
|
123
|
March 16, 2023
|
Does conventional decision curve assume no reduction in absolute risk?
|
|
8
|
246
|
March 15, 2023
|
Sample size estimation for observational studies using Bayesian methods
|
|
2
|
110
|
March 15, 2023
|
Using trajectory analysis and G-formula in observational data
|
|
6
|
185
|
March 13, 2023
|
Discrimination, calibration and other metrics: can they tell us about the clinical value of a model?
|
|
12
|
3152
|
March 13, 2023
|
The relation between Statistical Inference and Causal Inference
|
|
15
|
4659
|
March 13, 2023
|
Model to assess length of stay (LOS)
|
|
10
|
227
|
March 12, 2023
|
Heteroskedasticity and Non-normality together; few solutions exist
|
|
1
|
98
|
March 9, 2023
|
Appropriate model for combined data from two RCTs
|
|
10
|
160
|
March 8, 2023
|
Bayesian Regression Modeling Strategies
|
|
47
|
3499
|
March 8, 2023
|
RCT with missing follow-up outcomes: ANCOVA + MI vs Mixed-Effects Modelling?
|
|
50
|
2158
|
March 7, 2023
|
FDA "Bad Habits"
|
|
7
|
769
|
March 4, 2023
|
Regression coefficients requirement for calibration plot
|
|
4
|
143
|
March 4, 2023
|
Descriptive Stats Interpreting Standard deviation
|
|
4
|
157
|
March 3, 2023
|
Multifractional polynomial with mixed-effects logistic model
|
|
3
|
96
|
March 2, 2023
|
Strategies to overcome referral \ workup bias in Diagnosis Prediction Models
|
|
6
|
144
|
March 2, 2023
|
RMS Describing, Resampling, Validating, and Simplifying the Model
|
|
92
|
32944
|
March 1, 2023
|
Using Net Benefit and Decision Curve Analysis to pre-specify target model performance
|
|
4
|
200
|
February 28, 2023
|
Bayesian Biostatistical Modeling Plan
|
|
6
|
597
|
February 28, 2023
|
Minimum PPV/NPV values to reach positive net benefit and net benefit avoided
|
|
8
|
169
|
February 27, 2023
|
Minimum sample size for ROC analysis
|
|
1
|
114
|
February 26, 2023
|